ArticleJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2026
Long-term disease control of disseminated superficial actinic porokeratosis (DSAP) with simvastatin 2%/ cholesterol 2% cream.
Article in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [2 % Simvastatin/2 % cholesterol cream in disseminated superficial actinic porokeratosis effectively and safely used long-term : Case report and retrospective survey of 14 patients].Dermatologie (Heidelberg, Germany) · 2026Article
- Efficacy and safety of topical statins for porokeratosis: a systematic review and practice-guided synthesis.Skin health and disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDisseminated superficial actinic porokeratosis (DSAP) is a rare keratinization disorder associated with an increased risk of cutaneous tumors.
objectivesTo develop a feasible and easy-to-apply treatment regimen for long-time disease control of DSAP including prevention of new skin tumors. PATIENTS AND
methods19 patients with DSAP were treated with 2% simvastatin/2% cholesterol (SC) cream for a maximum period of 18 months. Disease severity was assessed via Investigator Global Assessment (IGA), and quality of life (QoL) was measured using the Dermatology Life Quality Index (DLQI). Adverse events and tumor development were documented.
resultsSignificant improvement in IGA scores was observed across all treated regions (p < 0.001), with most progress occurring in the first 3 months but maintained under a reduced proactive application schedule twice weekly. DLQI scores decreased significantly within the first 3 months. No new skin tumors developed during treatment.
conclusionsSC cream is a promising long-term, targeted treatment for DSAP, offering sustained efficacy, good tolerability, and improved QoL. The individual tapering from daily use to a proactive approach twice a week may be a key factor for disease control and may become an important component of skin tumor prevention in this specific patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.